Literature DB >> 35674284

Lesion size and shape in central vein sign assessment for multiple sclerosis diagnosis: An in vivo and postmortem MRI study.

Omar Al-Louzi1, Sargis Manukyan1, Maxime Donadieu2, Martina Absinta3, Vijay Letchuman2, Brent Calabresi2, Parth Desai4, Erin S Beck5, Snehashis Roy6, Joan Ohayon7, Dzung L Pham8, Anish Thomas4, Steven Jacobson9, Irene Cortese7, Pavan K Auluck10, Govind Nair2, Pascal Sati1, Daniel S Reich2.   

Abstract

BACKGROUND: The "central vein sign" (CVS), a linear hypointensity on T2*-weighted imaging corresponding to a central vein/venule, is associated with multiple sclerosis (MS) lesions. The effect of lesion-size exclusion criteria on MS diagnostic accuracy has not been extensively studied.
OBJECTIVE: Investigate the optimal lesion-size exclusion criteria for CVS use in MS diagnosis.
METHODS: Cross-sectional study of 163 MS and 51 non-MS, and radiological/histopathological correlation of 5 MS and 1 control autopsy cases. The effects of lesion-size exclusion on MS diagnosis using the CVS, and intralesional vein detection on histopathology were evaluated.
RESULTS: CVS+ lesions were larger compared to CVS- lesions, with effect modification by MS diagnosis (mean difference +7.7 mm3, p = 0.004). CVS percentage-based criteria with no lesion-size exclusion showed the highest diagnostic accuracy in differentiating MS cases. However, a simple count of three or more CVS+ lesions greater than 3.5 mm is highly accurate and can be rapidly implemented (sensitivity 93%; specificity 88%). On magnetic resonance imaging (MRI)-histopathological correlation, the CVS had high specificity for identifying intralesional veins (0/7 false positives).
CONCLUSION: Lesion-size measures add important information when using CVS+ lesion counts for MS diagnosis. The CVS is a specific biomarker corresponding to intralesional veins on histopathology.

Entities:  

Keywords:  Biomarkers; T2 lesions; central vein sign; magnetic resonance imaging; multiple sclerosis; post mortem

Mesh:

Year:  2022        PMID: 35674284      PMCID: PMC9489648          DOI: 10.1177/13524585221097560

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   5.855


  33 in total

1.  Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI.

Authors:  E C Tallantyre; M J Brookes; J E Dixon; P S Morgan; N Evangelou; P G Morris
Journal:  Neurology       Date:  2008-05-27       Impact factor: 9.910

2.  The ovoid lesion: a new MR observation in patients with multiple sclerosis.

Authors:  A L Horowitz; R D Kaplan; G Grewe; R T White; L M Salberg
Journal:  AJNR Am J Neuroradiol       Date:  1989 Mar-Apr       Impact factor: 3.825

3.  Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Authors:  Massimo Filippi; Paolo Preziosa; Alessandro Meani; Olga Ciccarelli; Sarlota Mesaros; Alex Rovira; Jette Frederiksen; Christian Enzinger; Frederik Barkhof; Claudio Gasperini; Wallace Brownlee; Jelena Drulovic; Xavier Montalban; Stig P Cramer; Alexander Pichler; Marloes Hagens; Serena Ruggieri; Vittorio Martinelli; Katherine Miszkiel; Mar Tintorè; Giancarlo Comi; Iris Dekker; Bernard Uitdehaag; Irena Dujmovic-Basuroski; Maria A Rocca
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

4.  Diagnostic performance of central vein sign for multiple sclerosis with a simplified three-lesion algorithm.

Authors:  Andrew J Solomon; Richard Watts; Daniel Ontaneda; Martina Absinta; Pascal Sati; Daniel S Reich
Journal:  Mult Scler       Date:  2017-08-18       Impact factor: 6.312

5.  Preventing multiple sclerosis misdiagnosis using the "central vein sign": A real-world study.

Authors:  Marwa Kaisey; Andrew J Solomon; Brooke L Guerrero; Brian Renner; Zhaoyang Fan; Natalie Ayala; Michael Luu; Marcio A Diniz; Pascal Sati; Nancy L Sicotte
Journal:  Mult Scler Relat Disord       Date:  2020-12-15       Impact factor: 4.339

6.  Postmortem magnetic resonance imaging to guide the pathologic cut: individualized, 3-dimensionally printed cutting boxes for fixed brains.

Authors:  Martina Absinta; Govind Nair; Massimo Filippi; Abhik Ray-Chaudhury; Maria I Reyes-Mantilla; Carlos A Pardo; Daniel S Reich
Journal:  J Neuropathol Exp Neurol       Date:  2014-08       Impact factor: 3.685

7.  CVSnet: A machine learning approach for automated central vein sign assessment in multiple sclerosis.

Authors:  Pietro Maggi; Mário João Fartaria; João Jorge; Francesco La Rosa; Martina Absinta; Pascal Sati; Reto Meuli; Renaud Du Pasquier; Daniel S Reich; Meritxell Bach Cuadra; Cristina Granziera; Jonas Richiardi; Tobias Kober
Journal:  NMR Biomed       Date:  2020-03-03       Impact factor: 4.478

8.  Central vein sign differentiates Multiple Sclerosis from central nervous system inflammatory vasculopathies.

Authors:  Pietro Maggi; Martina Absinta; Matteo Grammatico; Luisa Vuolo; Giacomo Emmi; Giovanna Carlucci; Gregorio Spagni; Alessandro Barilaro; Anna Maria Repice; Lorenzo Emmi; Domenico Prisco; Vittorio Martinelli; Roberta Scotti; Niloufar Sadeghi; Gaetano Perrotta; Pascal Sati; Bernard Dachy; Daniel S Reich; Massimo Filippi; Luca Massacesi
Journal:  Ann Neurol       Date:  2018-02-15       Impact factor: 10.422

9.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

10.  Utility of shape evolution and displacement in the classification of chronic multiple sclerosis lesions.

Authors:  Darin T Okuda; Tatum M Moog; Morgan McCreary; Jennifer N Bachand; Andrew Wilson; Katy Wright; Mandy D Winkler; Osniel Gonzalez Ramos; Aiden P Blinn; Yeqi Wang; Thomas Stanley; Marco C Pinho; Braeden D Newton; Xiaohu Guo
Journal:  Sci Rep       Date:  2020-11-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.